Journal of Feline Medicine and Surgery最新文献

{"title":"Evaluation of the efficacy and safety of toceranib phosphate in cats with macroscopic mammary adenocarcinoma.","authors":"Isabel Del Portillo Miguel, Laura Blackwood, Elisa Maiques, Ignacio Pérez Roger, Enric Poch Jiménez, Juan Borrego","doi":"10.1177/1098612X241256473","DOIUrl":"10.1177/1098612X241256473","url":null,"abstract":"<p><strong>Objectives: </strong>Mammary tumours in cats are biologically aggressive. The standard of care relies upon wide surgical resection. Chemotherapy has been described in the macroscopic disease setting; however, limited efficacy has been shown. The aim of this study was to assess the efficacy of toceranib phosphate in macroscopic feline mammary tumours (FMTs).</p><p><strong>Methods: </strong>A total of 17 cats with cytologically or histopathologically confirmed mammary adenocarcinoma (gross disease) were prospectively enrolled. Toceranib phosphate was administered at a median dose of 2.77 mg/kg (range 2.3-3.2) PO q48 h. No corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) were administered. Toxicity was graded according to Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v1.1 criteria. The response was assessed after 1 month, following Response Evaluation Criteria In Solid Tumours (RECIST) criteria.</p><p><strong>Results: </strong>Toxicity was observed in eight cats, with most instances being grade 1 or 2, which were managed with supportive care. Only one cat experienced grade 3 toxicity (anorexia), which resolved after a dose reduction. Clinical benefit was seen in 12 (64.7%) cats and an objective response was seen in six (35.2%) cats. One cat experienced complete response, five had partial response, six had stable disease and five had progressive disease. One cat showed distant progression (malignant pleural effusion) despite continued partial remission of the primary tumour. The median progression-free survival and median overall survival time were 91 days (range 30-158) and 145 days (range 31-234), respectively.</p><p><strong>Conclusions and relevance: </strong>Toceranib phosphate showed clinical benefit and a good safety profile in advanced or recurrent FMTs, offering a new alternative in the treatment of this disease; however, further prospective and randomised studies are required to further assess its efficacy. Interestingly, one cat developed distant metastases while the primary tumour showed partial response, suggesting that primary tumour and metastatic disease may not sustain the same sensitivity to toceranib.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241256473"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of veterinarians in the USA to evaluate trends in the treatment approach for non-obstructive feline idiopathic cystitis.","authors":"Laurel R Krause, Emma Li, M Leanne Lilly, Julie Byron, Edward Cooper, Jessica Quimby","doi":"10.1177/1098612X241260716","DOIUrl":"10.1177/1098612X241260716","url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this study was to gather information on treatment approaches and trends for the treatment of non-obstructive feline idiopathic cystitis (FIC).</p><p><strong>Methods: </strong>An internet-based survey of veterinarians was conducted focusing on outpatient treatment approaches for cats that are stable, not obstructed and that exhibit lower urinary signs suspected to be due to FIC, where other causes (eg, urolithiasis, urinary tract infection, other) have been ruled out.</p><p><strong>Results: </strong>A total of 606 veterinarians submitted complete surveys for inclusion. Respondents reported that when obtaining patient histories, in ⩾75% of client interactions they gathered information about feline stressors (542/606, 89%), resource set-up (eg, number of litter boxes; 466/606, 77%) and diet (552/606, 91%). Only 31% (187/606) of respondents reported that they gathered information about daily human/cat interaction in ⩾75% of client interactions, with 69% (419/606) of veterinarians inquiring about this information 50% of the time or less. Top treatments selected for acute presentations of FIC were analgesics (537/606, 89%), modified litter box management (435/606, 72%) and synthetic feline pheromones (422/606, 70%). Top treatments selected for chronic FIC management were prescription diets (519/606, 86%), modified litter box management (508/606, 84%) and environmental enhancements (493/606, 81%). Challenges with owner compliance and expectations were selected as barriers to achieving a positive treatment outcome by 81% (486/599) and 62% (372/599) of respondents, respectively. Rehoming or euthanasia were recommended by 37% (224/606) and 10% (59/606) of veterinarians, respectively, due to difficulties managing FIC.</p><p><strong>Conclusions and relevance: </strong>The treatment approach for non-obstructive FIC appears to be multimodal and recommendations vary between acute and chronic presentations. An area of opportunity is client communication and education, which may improve owner compliance and help set appropriate expectations. The importance of human/cat interaction as a management strategy appears under-emphasized.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241260716"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody response after feline panleukopenia virus vaccination in kittens with and without intestinal parasites.","authors":"Anna-Karina Weidinger, Katrin Hartmann, Dieter Barutzki, Uwe Truyen, Ahmed Abd El Wahed, Yury Zablotski, Michèle Bergmann","doi":"10.1177/1098612X241264731","DOIUrl":"10.1177/1098612X241264731","url":null,"abstract":"<p><strong>Objectives: </strong>Vaccinations should only be given to healthy cats, and deworming before vaccination is generally recommended; however, so far, no study has investigated the influence of intestinal parasitic infection on the immune response in kittens. The aim of this prospective study was to compare the antibody response to feline panleukopenia virus (FPV) vaccination in kittens with and without intestinal parasites.</p><p><strong>Methods: </strong>Overall, 74 healthy kittens were included. Of these, 17 had intestinal parasites (12/17 <i>Toxocara cati</i>, 6/17 <i>Cystoisospora felis</i>, 1/17 <i>Capillaria</i> species). Both kittens with and without (n = 57) parasites received two primary kitten vaccinations with modified live FPV vaccines in a 4-week interval starting at the age of 8-12 weeks. Anti-FPV antibodies were determined at the beginning of the study (week 0) and at week 8 (4 weeks after the second vaccination) by haemagglutination inhibition. A ⩾four-fold titre increase (week 8 vs week 0) was defined as a response to vaccination. Comparison of the immune response in the kittens with and without intestinal parasites was performed using Pearson's χ² test.</p><p><strong>Results: </strong>Pre-vaccination antibodies were present in 4/17 (23.5%) kittens with intestinal parasites and in 24/57 (42.1%) without parasites. A ⩾four-fold titre increase was seen in 13/17 (76.5%) kittens with parasites compared with 32/57 (56.1%) kittens without parasites. There was neither a significant difference in pre-vaccination antibodies (<i>P</i> = 0.17), nor in vaccination response (<i>P</i> = 0.13) between kittens with and without parasites.</p><p><strong>Conclusions and relevance: </strong>The results indicate that asymptomatic intestinal infections with endoparasites do not interfere with the immune response to kitten vaccination series. Parasitic infection (at least with <i>T cati</i>, <i>C felis</i> and <i>Capillaria</i> species) is therefore not a reason to postpone important vaccinations.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241264731"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational use of gastroprotectants in cats: An evidence-based approach.","authors":"Katie Tolbert, Eric Stubbs","doi":"10.1177/1098612X241274235","DOIUrl":"10.1177/1098612X241274235","url":null,"abstract":"<p><strong>Practical relevance: </strong>Acid-related disorders including esophagitis and gastroduodenal ulceration are uncommon in the cat. However, when they occur, they can have devastating consequences and require targeted intervention, including the use of gastroprotectants. Careful consideration of the causes of esophagitis and gastroduodenal ulceration can help the clinician to determine which gastroprotectant to use, and when to begin and end gastroprotective therapy.</p><p><strong>Clinical challenges: </strong>Gastroprotectants remain one of the most misused classes of drugs in veterinary and human medicine. There are very few studies evaluating the efficacy of gastroprotective agents in cats. Furthermore, goals for the degree of gastric acid suppression are extrapolated from studies performed in dogs and humans.</p><p><strong>Aims: </strong>This review provides a foundation for the logical approach to the choice of gastroprotectant as indicated by the disease process, and is aimed at all veterinarians who prescribe gastroprotectants for use in cats.</p><p><strong>Evidence base: </strong>The guidance provided in this review is supported by current literature, including consensus opinion from the American College of Veterinary Internal Medicine. Gaps in evidence for use of gastroprotectants in cats are filled by extrapolations from studies performed in dogs and humans.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241274235"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid emulsion dosage for treatment as an adjuvant drug in the cat.","authors":"Ju-Tae Sohn, Sandra Lundgren","doi":"10.1177/1098612X241267181","DOIUrl":"10.1177/1098612X241267181","url":null,"abstract":"","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241267181"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasonic Doppler as a guide for feline peripheral arterial catheterization.","authors":"Satoshi Haginoya, Elizabeth J Thomovsky, Hsin-Yi Weng, Paula A Johnson, Aimee C Brooks","doi":"10.1177/1098612X241257857","DOIUrl":"10.1177/1098612X241257857","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to determine if an ultrasonic Doppler-guided technique (UDGT) leads to improved placement efficacy (time, success) of feline dorsal pedal arterial catheters vs the traditional palpation-guided technique (TPT).</p><p><strong>Methods: </strong>A total of 26 adult, client-owned cats requiring sedation or general anesthesia for any reason, aged >12 months and weighing >3.0 kg, and with Doppler blood pressure measurements of at least 80 mmHg were enrolled. Each hindlimb was randomly assigned for dorsal pedal arterial catheterization using either the UDGT or TPT. With the UDGT, the location of the artery was identified by an audible sound using the Doppler. Successful catheter placement was confirmed by visualization of an arterial pressure waveform using a transducer and monitor system attached to the catheter. The Kaplan-Meier method and log-rank test were used to compare the two techniques.</p><p><strong>Results: </strong>The overall proportion of successful arterial catheterization was 17% (9/52): 19% (5/26) via UDGT and 15% (4/26) via TPT. Among successful arterial catheterizations (n = 9), the mean time to catheterization was 339 ± 198 s: 328 ± 237 s (n = 5) with UDGT and 353 ± 171 s (n = 4) with TPT. The log-rank test showed the two techniques were not significantly different in likelihood of successful arterial catheter placement or time to successful catheterization (<i>P</i> = 0.698). An arterial flash occurred in 62% (32/52) of the limbs, 58% (15/26) with the UDGT and 65% (17/26) with the TPT. Complications (self-limiting bruising, hematoma formation) were observed equally between UDGT (3/26 limbs) and TPT (3/26 limbs) in six cats.</p><p><strong>Conclusions and relevance: </strong>The UDGT did not improve the efficacy of catheter placement compared with the TPT. Few complications were associated with arterial catheterization.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241257857"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related trends in urine specific gravity in apparently healthy cats.","authors":"Adam J Rudinsky, Valerie J Parker, JoAnn Morrison, Nathaniel Spofford, Melica Nikahd, Kseniya Topdjian, Julie M Byron, Jenessa A Winston, Cathy Langston, Jessica M Quimby","doi":"10.1177/1098612X241256469","DOIUrl":"10.1177/1098612X241256469","url":null,"abstract":"<p><strong>Objectives: </strong>Urine specific gravity (USG) is the most common method for the estimation of urine concentration in cats. Utilization of USG as a screening tool is easily accessible and is of low cost to the client if strategically utilized in settings of higher diagnostic value. There is currently minimal population information regarding how USG changes across ages in cats.</p><p><strong>Methods: </strong>Data were collected from electronic pet medical records from more than 1000 hospitals and screened for cats with an apparently healthy clinical status and complete diagnostic information. USG was compared with age in multiple analyses to examine the relationship between the variables.</p><p><strong>Results: </strong>In the absence of other indicators of disease, renal concentrating ability begins to diminish, on average, starting at approximately 9 years of age. By age group, cats aged 11-15 years (1.044, 95% confidence interval [CI] 1.043-1.044) had statistically significantly lower mean USGs compared with cats aged less than 1 year (1.049, 95% CI 1.048-1.051; <i>P</i> <0.001), 1-6 years (1.049, 95% CI 1.049-1.050; <i>P</i> <0.001) or 7-10 years (1.049, 95% CI 1.048-1.049; <i>P</i> <0.001). Cats aged ⩾15 years (1.038, 95% CI 1.036-1.040) had statistically significantly lower mean USGs compared with cats aged less than 1 year (<i>P</i> <0.001), 1-6 years (<i>P</i> <0.001), 7-10 years (<i>P</i> <0.001) or 11-15 years (<i>P</i> <0.001).</p><p><strong>Conclusions and relevance: </strong>Renal concentrating ability begins to diminish, on average, starting at approximately 9 years of age and is progressive as cat age increases. This study provides important and new information to help improve screening practices for disorders of concentrating ability in cats.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241256469"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"US cat caregivers' attitudes on veterinary video telemedicine.","authors":"Sooyoung Lee, Grace Boone, Ashley Bidgoli, Joshua Di Bernardo, Carly M Moody","doi":"10.1177/1098612X241249623","DOIUrl":"10.1177/1098612X241249623","url":null,"abstract":"<p><strong>Objectives: </strong>Many cats do not see a veterinarian on an annual basis, and their caregivers face many barriers to accessing veterinary care. A potential solution to overcome some of these barriers is video telemedicine. Thus, the aim of this study was to understand companion cat caregivers' perceptions of using veterinary video telemedicine with their cats.</p><p><strong>Methods: </strong>An online quantitative questionnaire was used to survey US cat caregivers on their experiences of and attitudes to using video telemedicine with their cats. Participants were required to reside in the USA, be the primary caregiver of at least one cat and be aged 18 years or older.</p><p><strong>Results: </strong>The majority (97.3%) of the 1254 respondents indicated they had never used a video telemedicine appointment with their cat(s) before; however, most (85.7%) indicated they were very or somewhat interested in using video telemedicine with their cat. Overall, caregivers perceived video telemedicine visits as less stressful for themselves (<i>P</i> <0.0002) and their cats (<i>P</i> <0.0001), and as increasing their access to veterinary care (<i>P</i> <0.0001) compared with in-clinic visits. Participants also indicated they would prefer a video telemedicine appointment over an in-clinic appointment for most cat behavioral concerns but preferred in-clinic appointments for most health concerns. Most respondents (51.3%) indicated they would be willing to pay a little less for a telemedicine appointment than an in-clinic visit.</p><p><strong>Conclusions and relevance: </strong>Cat caregivers represent an important population that could benefit from the implementation of video telemedicine into veterinary care. Our results suggest many US cat caregivers indicate an interest and willingness to pay for video telemedicine visits to increase their access to veterinary care and reduce stress associated with veterinary visits for both themselves and their cats. Caregivers showed more interest in using video telemedicine for behavioral concerns than health concerns.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 8","pages":"1098612X241249623"},"PeriodicalIF":1.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Description of outcome and adverse events in 21 cats with locally advanced nasal planum squamous cell carcinoma treated with electrochemotherapy.","authors":"Elena Ferrer-Jorda, Ignacio Rodríguez-Pizà","doi":"10.1177/1098612X241248043","DOIUrl":"10.1177/1098612X241248043","url":null,"abstract":"<p><strong>Objectives: </strong>Squamous cell carcinoma (SCC) is the most common tumour in the nasal planum of cats. Surgery has traditionally been the treatment of choice but might not be feasible in locally advanced scenarios. Electrochemotherapy (ECT) has shown good control in superficial tumours, but there is a lack of robust information about efficacy in locally advanced cases. The aim of this study was to assess the safety and efficacy of ECT in the treatment of locally advanced stage nasal planum SCC in cats.</p><p><strong>Methods: </strong>The clinical database of a veterinary referral hospital was searched retrospectively for cats diagnosed with a locally advanced nasal planum SCC (T₃N₀M₀ or T₄N₀M₀) that had received ECT. Local response, adverse events and outcome were documented. The data were evaluated by inferential statistics and correlations between response, recurrence, feline immunodeficiency virus/feline leukaemia virus status, number of treatments, voltage and severity of adverse events, with Kaplan-Meier curves and log-rank tests. Statistical significance was set at <i>P</i> <0.05.</p><p><strong>Results: </strong>In total, 21 cats were enrolled over a 4-year period. Nineteen cats achieved a complete response (CR) and two cats a partial response (PR) for an overall response rate of 100%. Cats achieving a CR had a median disease-free interval of 182 days (range 128-327) and those with a PR had a median progression-free survival of 156.5 days (range 122-191). The median time to progression was not reached. The overall survival was 453 days for a median follow-up of 341 days (range 191-989). Of the cats, 62% had grade 3 or 4 toxicities, but no deaths due to the treatment were documented. Only voltage was correlated with longer survival (<i>P</i> = 0.001).</p><p><strong>Conclusions and relevance: </strong>ECT appears to be an effective treatment for feline nasal planum SCC and could be considered a first-line therapy for locally advanced cases. Toxicities reported can be severe in the short term and these could be secondary to more invasive lesions and equipment used.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 7","pages":"1098612X241248043"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of feline immunodeficiency virus prevalence and expert opinions on standards of care.","authors":"Mary Nehring, Ellyn M Dickmann, Kara Billington, Sue VandeWoude","doi":"10.1177/1098612X241245046","DOIUrl":"10.1177/1098612X241245046","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to identify knowledge gaps in the global prevalence of feline immunodeficiency virus (FIV) and to obtain professional opinions and experiences regarding FIV in selected countries. We conducted a literature review of abstracts that reported the prevalence of FIV and interviewed experts in feline medicine and retroviruses from different countries to determine regional perspectives.</p><p><strong>Methods: </strong>A total of 90 articles reporting FIV prevalence as a primary unbiased population-level analysis between 1980 and 2017 were indexed. FIV prevalence, demographics, year and location were analyzed. Statistics were evaluated and compared. In total, 10 experts were interviewed. Results were analyzed for congruence with the findings of the literature review.</p><p><strong>Results: </strong>FIV prevalence was typically in the range of 5-8%, with a global prevalence of 4.7%, and remained largely constant over the reporting period (1980-2017). Over 90% of articles reported greater prevalence in older male cats. More studies were conducted in North America and Europe and reported the lowest prevalence. Expert-estimated prevalence approximated literature review prevalence. Attitudes and recommendations for management were consistent among experts. The limitations of the present review include varying inclusion criteria of cats tested in different studies, variation in testing modalities and the inability to conduct summary statistics across dissimilar cohorts.</p><p><strong>Conclusions and relevance: </strong>The global prevalence of FIV has not changed since its discovery 40 years ago. Prevalence is higher in older male cats and is lower in North America and Europe than other continents. Experts agree that FIV is not typically a disease of high concern and is often associated with infections of the oral cavity. Vaccination is not typically recommended and has been discontinued in North America. The evaluation of risk factors for FIV progression is useful in managing infections. Recommendations for future research include analyses to determine copathogen and environmental factors that impact progression, assessment of life span impacts and investigations of treatment efficacy and side effects.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"26 7","pages":"1098612X241245046"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}